Aspira Pathlab & Diagnostics Limited - healthcare in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L85100MH1973PLC289209 Incorporated 03 July 1973 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 540788 Public Limited Company healthcare MSME · Small
Market Cap
₹135 Cr
ASPIRA · BSE
Share Price
₹137.55
+5.00% today
Revenue
₹22.00 Cr
FY 2024-25 · +66.7% YoY
EBITDA
₹3.47 Cr
Margin 15.8%
Net Profit
₹2.05 Cr
FY 2024-25 · +176.2% YoY
P/E (TTM)
55.4x
P/B 18.4x
ROE
16.5%
ROCE 11.5%
Debt / Equity
0.15
Interest cover 17.7x

About Aspira Pathlab & Diagnostics Limited

Data last updated:

Aspira Pathlab & Diagnostics Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 03 July 1973 and has been in existence for over 53 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L85100MH1973PLC289209. Its GSTIN is 27AAACU3049G1ZF (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 540788.

The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹15.79 Cr. It was formerly known as Utkal Soap Products Ltd and Industrial Gas & Steel Products (India) Limited. It is led by directors including Pankaj Jashwant Shah (Managing Director) and Manas Rajendra Mengar.

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹24.98 Cr, a growth of 13.5% compared to the previous year. For the same year it recorded a net profit of ₹5 Lakh (net margin 0.2%) and EBITDA of ₹1.46 Cr (EBITDA margin 5.8%). The net worth stands at ₹13.58 Cr (up 1.2% YoY). Total assets are valued at ₹16.27 Cr (up 1.9% YoY).

The company has about 62 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Aspira Diagnostics. As per MCA filings, the company has satisfied charges of ₹6.22 Cr on record. Court records list 5 cases involving the company, including 3 filed by the company and 2 filed against it; 1 case is pending. The company has 3 deals on record (3 market trades); the latest was in July 2018.

Aspira Pathlab & Diagnostics Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0027317). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aspiradiagnostics.com.

Company details

CIN L85100MH1973PLC289209
Registration Number 289209
Incorporation Date 03 July 1973
ROC Mumbai
Listing Status Listed - Listed on BSE (540788)
Company Status Active
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-19-0027317

Name history

Aspira Pathlab & Diagnostics has undergone 3 name changes throughout its history. The company was previously known as Utkal Soap Products Ltd, Industrial Gas & Steel Products (India) Limited, and Utkal Soap Products Limited. The current legal name is Aspira Pathlab & Diagnostics Limited.

Company NameStatus
Aspira Pathlab & Diagnostics LimitedCurrent
Utkal Soap Products LtdPrevious
Industrial Gas & Steel Products (India) LimitedPrevious
Utkal Soap Products LimitedPrevious

CIN history

Aspira Pathlab & Diagnostics has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L85100MH1973PLC289209, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L85100MH1973PLC289209Current
L51909WB1973PLC028878Previous
L85100WB1973PLC028878Previous

Recognitions & Rankings of Aspira Pathlab & Diagnostics

MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-MH-19-0027317

Contact details

Aspira Pathlab & Diagnostics Limited's registered office is in Mumbai, Maharashtra. Its website is aspiradiagnostics.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Apps
  • Registered Address
    Flat No.2 R.D. Shah Bldg Shraddhanand Road Opp. Ghatkopar Railway Station Ghatkopa, R (West), Mumbai, Maharashtra, India – 400086
  • Industry
    Healthcare, Diagnostic Centers & Pathology Labs

To see the full contact details of Aspira Pathlab & Diagnostics Limited, buy the company report.

Comprehensive company report
Aspira Pathlab & Diagnostics Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Aspira Pathlab & Diagnostics operates one associated brand: Aspira Diagnostics. Each brand links to its own profile.

BrandDescriptionWebsite
Pathology lab services are operated through a chain of facilities.aspiradiagnostics.com

Business activity

The main business activity of Aspira Pathlab & Diagnostics is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
QHospital and Medical CareQ2Medical and dental practice, Nursing, pathology, blood bank services, etc.

To see the full business activity and turnover split of Aspira Pathlab & Diagnostics Limited, buy the company report.

Financials of Aspira Pathlab & Diagnostics Limited

FY 2025-26 filings available

Aspira Pathlab & Diagnostics Limited reported revenue of ₹24.98 Cr (up 13.5% YoY) for FY 2025-26.

Financial Highlights

FY 2024-25 · Consolidated
Revenue
₹22.00 Cr
+66.7% YoY
EBITDA
₹3.47 Cr
+389.2% YoY
Profit After Tax
₹2.05 Cr
+176.2% YoY
Net Worth
₹13.37 Cr
+19.2% YoY
Total Assets
₹15.92 Cr
+19.3% YoY
Total Debt
₹1.99 Cr
+17.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2024-25FY 2023-24
Income statement
Revenue22.0013.20
Revenue growth+66.7%-
EBITDA3.47(1.20)
EBITDA margin+15.8%-9.1%
Profit before tax2.02(2.69)
Net profit2.05(2.69)
Net profit margin+9.3%-20.4%
EPS (₹)1.97(2.60)
Balance sheet
Total assets15.9213.34
Net worth13.3711.22
Total debt1.991.70
Cash & bank2.141.38
Net working capital3.812.98
Cash flow
Cash from operations1.831.05
Cash from investing0.120.14
Cash from financing(0.99)(0.95)
ParticularsJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Jun 2023
Revenue5.255.785.416.184.643.822.60
Revenue growth (YoY)+13.2%+51.3%--+78.5%--
Other income0.110.130.090.080.160.080.10
EBITDA0.680.920.611.280.27(0.20)(0.43)
EBITDA margin+13.0%+15.9%+11.3%+20.7%+5.8%-5.2%-16.5%
Depreciation0.370.370.390.360.380.380.39
Interest0.000.000.000.000.000.000.00
Profit before tax0.420.680.311.000.05(0.50)(0.72)
Tax0.000.000.000.000.000.000.00
Net profit0.420.680.311.000.05(0.50)(0.72)
EPS (₹)0.410.660.300.960.05(0.49)(0.70)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24.9822.0013.2014.4619.5415.218.42
Revenue growth+13.6%+66.7%-8.7%-26.0%+28.5%+80.6%-
EBITDA1.463.52(1.20)1.606.373.52(1.84)
EBITDA margin+5.8%+16.0%-9.1%+11.1%+32.6%+23.1%-21.9%
Profit before tax0.052.07(2.69)(0.09)4.451.39(4.22)
Net profit0.052.10(2.69)(0.09)4.451.39(4.25)
Net profit margin+0.2%+9.6%-20.4%-0.6%+22.8%+9.1%-50.5%
EPS (₹)0.052.01(2.60)(0.09)4.331.34(4.56)
Balance sheet
Total assets16.2715.9713.3416.4316.9910.6012.90
Net worth13.5813.4211.2213.7113.659.084.49
Total debt1.971.991.702.353.061.318.19
Cash & bank1.682.141.382.351.641.191.10
Net working capital2.353.812.984.955.992.701.85
Cash flow
Cash from operations1.451.881.05(0.01)2.035.67(1.87)
Cash from investing(0.80)0.070.140.16(0.51)(0.09)0.24
Cash from financing(1.14)(0.99)(0.95)(0.94)(1.35)(2.17)1.27
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6.266.176.525.128.095.255.785.41
Revenue growth (YoY)-22.6%+17.5%+12.8%-5.4%+30.9%+13.2%--
Other income0.090.120.140.130.140.110.130.09
Total expenses6.945.836.866.335.904.434.724.64
EBITDA(0.68)0.34(0.34)(1.21)2.190.821.060.77
EBITDA margin-10.9%+5.5%-5.2%-23.6%+27.1%+15.6%+18.3%+14.2%
Depreciation0.460.410.400.380.400.370.370.39
Interest0.110.090.100.100.100.090.090.09
Profit before tax(1.16)(0.04)(0.70)(1.56)1.830.470.730.38
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Jun 2023
Revenue5.255.785.416.184.643.822.60
Revenue growth (YoY)+13.2%+51.3%--+78.5%--
Other income0.110.130.090.080.160.080.10
EBITDA0.680.920.611.280.27(0.20)(0.43)
EBITDA margin+13.0%+15.9%+11.3%+20.7%+5.8%-5.2%-16.5%
Depreciation0.370.370.390.360.380.380.39
Interest0.000.000.000.000.000.000.00
Profit before tax0.420.680.311.000.05(0.50)(0.72)
Tax0.000.000.000.000.000.000.00
Net profit0.420.680.311.000.05(0.50)(0.72)
EPS (₹)0.410.660.300.960.05(0.49)(0.70)
ParticularsFY 2024-25FY 2023-24
Revenue22.0013.20
Revenue growth+66.7%-
Other income0.390.42
Total expenses18.5314.40
Employee cost7.336.20
EBITDA3.47(1.20)
EBITDA margin+15.8%-9.1%
Depreciation1.491.54
Interest0.350.37
Profit before tax2.02(2.69)
Tax0.000.00
Net profit2.05(2.69)
Net profit margin+9.3%-20.4%
EPS (₹)1.97(2.60)
ParticularsFY 2024-25FY 2023-24
Equity & liabilities
Share capital16.4316.30
Reserves & surplus(3.06)(5.08)
Shareholders' funds (net worth)13.3711.22
Minority interest0.000.00
Secured loans0.000.00
Unsecured loans1.991.70
Total debt1.991.70
Total liabilities15.9213.34
Assets
Gross block18.3117.20
Net block6.536.79
Capital work in progress0.000.00
Investments0.080.00
Inventories0.510.45
Sundry debtors2.352.24
Cash & bank balances2.141.38
Loans & advances0.360.28
Total current assets5.364.35
Total current liabilities1.551.37
Net working capital3.812.98
Total assets15.9213.34
ParticularsFY 2024-25FY 2023-24
Opening cash0.800.57
Net cash from operating activities1.831.05
Net cash from investing activities0.120.14
Net cash from financing activities(0.99)(0.95)
Net change in cash0.950.24
Closing cash2.141.38
ParticularsFY 2024-25FY 2023-24
Growth
Sales growth+66.7%-
EBITDA growth+389.2%-
PBT growth+9998.0%+9997.0%
Net income growth+176.2%-
Profitability & leverage
Net income margin+9.2%-20.4%
Return on capital employed+11.5%0.0%
Return on net worth+16.5%0.0%
Debt / equity0.150.15
Long-term debt / equity0.090.09
Interest cover17.68-13.50
Efficiency & per share
Fixed asset turnover1.240.77
Inventory turnover45.8329.33
Debtors turnover9.595.89
EPS (₹)1.97(2.60)
Dividend per share (₹)0.000.00
Book value per share (₹)7.035.07
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6.266.176.525.128.095.255.785.41
Revenue growth (YoY)-22.6%+17.5%+12.8%-5.4%+30.9%+13.2%--
Other income0.090.120.140.130.140.110.130.09
Total expenses6.945.836.866.335.904.434.724.64
EBITDA(0.68)0.34(0.34)(1.21)2.190.821.060.77
EBITDA margin-10.9%+5.5%-5.2%-23.6%+27.1%+15.6%+18.3%+14.2%
Depreciation0.460.410.400.380.400.370.370.39
Interest0.110.090.100.100.100.090.090.09
Profit before tax(1.16)(0.04)(0.70)(1.56)1.830.470.730.38
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24.9822.0013.2014.4619.5415.218.42
Revenue growth+13.6%+66.7%-8.7%-26.0%+28.5%+80.6%-
Other income0.520.390.420.320.090.200.29
Total expenses23.5218.4814.4012.8613.1711.6910.26
Employee cost0.007.336.205.595.024.034.95
EBITDA1.463.52(1.20)1.606.373.52(1.84)
EBITDA margin+5.8%+16.0%-9.1%+11.1%+32.6%+23.1%-21.9%
Depreciation1.541.491.541.591.641.441.66
Interest0.390.350.370.420.370.891.01
Profit before tax0.052.07(2.69)(0.09)4.451.39(4.22)
Tax0.000.000.000.000.000.000.03
Net profit0.052.10(2.69)(0.09)4.451.39(4.25)
Net profit margin+0.2%+9.6%-20.4%-0.6%+22.8%+9.1%-50.5%
EPS (₹)0.052.01(2.60)(0.09)4.331.34(4.56)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.5716.4316.3016.1816.0815.9914.91
Reserves & surplus(2.99)(3.01)(5.08)(2.47)(2.43)(6.91)(10.42)
Shareholders' funds (net worth)13.5813.4211.2213.7113.659.084.49
Secured loans0.000.000.000.000.000.484.91
Unsecured loans1.971.991.702.353.060.833.28
Total debt1.971.991.702.353.061.318.19
Total liabilities16.2715.9713.3416.4316.9910.6012.90
Assets
Gross block20.5418.3117.2016.8816.8713.4112.91
Net block7.216.536.798.009.587.758.70
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.130.000.000.000.000.00
Inventories0.700.510.450.400.400.370.28
Sundry debtors1.732.352.242.344.491.700.60
Cash & bank balances1.682.141.382.351.641.191.10
Loans & advances0.470.360.280.770.600.621.31
Total current assets4.585.364.355.867.133.883.29
Total current liabilities2.231.551.370.911.141.181.44
Net working capital2.353.812.984.955.992.701.85
Total assets16.2715.9713.3416.4316.9910.6012.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.750.800.571.351.19(2.22)(1.87)
Net cash from operating activities1.451.881.05(0.01)2.035.67(1.87)
Net cash from investing activities(0.80)0.070.140.16(0.51)(0.09)0.24
Net cash from financing activities(1.14)(0.99)(0.95)(0.94)(1.35)(2.17)1.27
Net change in cash(0.49)0.950.24(0.79)0.173.41(0.35)
Closing cash1.682.141.382.351.641.191.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.6%+66.7%-8.7%-26.0%+28.5%+80.6%-
EBITDA growth-58.5%+393.3%-175.0%-74.9%+81.0%+291.3%-
PBT growth-97.6%+9998.0%-2888.9%-+220.1%+9998.0%+18.5%
Net income growth-97.6%+178.1%-2888.9%-102.0%+220.1%+132.7%-
Revenue CAGR (3Y)+20.0%+4.0%-4.6%+19.8%+36.8%+51.7%+122.9%
EBITDA CAGR (3Y)-3.0%-17.9%-----10.5%
Profitability & leverage
Net income margin+0.2%+9.4%-20.4%-0.6%+22.8%+9.1%-50.5%
Return on capital employed+1.6%+11.7%0.0%0.0%+17.6%+11.5%0.0%
Return on net worth+0.3%+16.9%0.0%0.0%+23.1%+15.2%0.0%
Debt / equity0.150.150.160.200.190.701.47
Long-term debt / equity0.080.090.110.150.130.370.84
Interest cover-487.5017.24-13.504,200.007.8242.79-28.86
Efficiency & per share
Fixed asset turnover1.291.240.770.861.291.160.69
Inventory turnover41.2945.8331.0636.1550.7546.8030.07
Debtors turnover12.259.595.764.236.3113.2312.03
EPS (₹)0.052.01(2.60)(0.09)4.331.34(4.56)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)7.097.085.077.607.643.29(1.21)

To see the full year-wise statements and ratios of Aspira Pathlab & Diagnostics Limited, buy the company report.

Board of directors of Aspira Pathlab & Diagnostics Limited

Aspira Pathlab & Diagnostics has 7 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Manas Rajendra MengarDirector12 Aug 20233 Years 3 MonthsCurrent
Vaibhav OdhekarAdditional Director23 May 20260 Years 5 MonthsCurrent
Kiran Raghavendra AwasthiDirector12 Nov 20251 Years 0 MonthsCurrent
Nikunj Velji MangeDirector29 Aug 20206 Years 2 MonthsCurrent
Haseeb Ahmad DrabuDirector27 Oct 20188 Years 0 MonthsCurrent
Pankaj Jashwant ShahManaging Director01 Aug 201610 Years 3 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Auditor

Aspira Pathlab & Diagnostics Limited is audited by P Khetan & Co. for the financial year 2024.

Auditor firmFinancial yearFirm registration number
P Khetan & Co.FY 2024327386E

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 18.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 81.60%.

Promoters: 18.40%Retail & Others: 81.60%
Mar 2026
QUARTER
18.40% Promoters
81.60% Retail & Others
Promoter holding - history
Now 18.40% · Mar 2026High 18.40% · Jun 2025Low 18.40% · Jun 2025
17%17.8%18.5%19.3%20%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 18.40%Sep 2025: 18.40%Dec 2025: 18.40%Mar 2026: 18.40%18.40%18.40%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters18.40%18.40%18.40%18.40%
Public81.60%81.60%81.60%81.60%

Charges & borrowings

Open charges
None
Satisfied charges
₹6.22 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹6.22 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
19 Jul 2020100359435Hdfc Bank Limited₹96.8 LakhSatisfied
04 Jun 2018100186823Hdfc Bank Limited₹50 LakhSatisfied
07 Dec 2016100077364Hdfc Bank Limited₹4.75 CrSatisfied

To see the full charge records of Aspira Pathlab & Diagnostics Limited, buy the company report.

Total charge records: 3 View all charges

Deals & funding

Aspira Pathlab & Diagnostics Limited has 3 deals on record (3 market trades); the latest was in July 2018.

Total deals
3
Market trades
3

Deals on record (3 of 3)

WhenDealAmountParties
Jul 2018Market trade₹5.3 LakhSeller: an individual
Apr 2018Market trade₹18.4 LakhBuyer: 2 individuals
Seller: 2 individuals
Feb 2018Market trade₹4.2 LakhBuyer: an individual
Seller: an individual

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Aspira Pathlab & Diagnostics Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Aspira Pathlab & Diagnostics Limited has a workforce of 62 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
62
Active EPFO establishments
1
Employee growth
-11.4%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-2762
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Aspira Pathlab & Diagnostics Limited, buy the company report.

GST

Aspira Pathlab & Diagnostics has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AAACU3049G1ZFMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Aspira Pathlab & Diagnostics Limited, buy the company report.

Recent activity

Aspira Pathlab & Diagnostics Limited has 25 board changes on record since 2010: 7 appointments and 18 cessations. The latest: Vaibhav Odhekar was appointed as Additional Director on 23 May 2026.

Appointed
Vaibhav Odhekar was appointed as Additional Director.
Filing
Aspira Pathlab & Diagnostics Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Ceased
Alaka Keshav Deshpande ceased to be Director.
Appointed
Kiran Raghavendra Awasthi was appointed as Director.
Ceased
Mangala Radhakrishna Prabhu ceased to be Director.
AGM
Aspira Pathlab & Diagnostics Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Appointed
Manas Rajendra Mengar was appointed as Director.
Ceased
Arvind Karsandas Bhanushali ceased to be Director.
Charges
A charge registered on 07 Dec 2016 via Charge ID 100077364 with Hdfc Bank Limited was fully satisfied on 07 Oct 2021.
Charges
A charge registered on 19 Jul 2020 via Charge ID 100359435 with Hdfc Bank Limited was fully satisfied on 18 Jun 2021.
Ceased
Abhay Sadashiv Chowdhary ceased to be Director.
Ceased
Yash Arvind Bhanushali ceased to be Director.

22 earlier events are in the company report.

Frequently asked questions

Aspira Pathlab & Diagnostics is an active public limited company based in Mumbai, Maharashtra, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 03 July 1973 (53+ years old) and is registered under CIN L85100MH1973PLC289209. Listed on BSE: 540788.

Aspira Pathlab & Diagnostics reported revenue of ₹24.98 Cr for FY 2025-26 (up 13.5% YoY) based on standalone financials.

Aspira Pathlab & Diagnostics has 7 current directors:

The latest financial statements of Aspira Pathlab & Diagnostics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Aspira Pathlab & Diagnostics is 27AAACU3049G1ZF, registered in Maharashtra.

The CIN (Corporate Identification Number) of Aspira Pathlab & Diagnostics is L85100MH1973PLC289209. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Aspira Pathlab & Diagnostics is a listed company as per MCA records. Its shares are listed on BSE (code: 540788).

Aspira Pathlab & Diagnostics has 5 court cases on record: 3 filed by the company and 2 filed against it. 1 is pending. Most are in the high courts.

Aspira Pathlab & Diagnostics was incorporated on 03 July 1973, making it 53+ years old. It is registered with the Registrar of Companies, Mumbai.

Aspira Pathlab & Diagnostics has 3 deals on record (3 market trades); the latest was in July 2018.